RA
MCID: RHM011
MIFTS: 80

Rheumatoid Arthritis (RA)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Rheumatoid Arthritis

MalaCards integrated aliases for Rheumatoid Arthritis:

Name: Rheumatoid Arthritis 57 11 42 75 73 28 53 5 41 2 14 36 63 16 71 33
Ra 57 42 73 2
Arthritis, Rheumatoid 42 43 38
Rheumatoid Arthritis, Susceptibility to 57 12
Arthritis or Polyarthritis, Rheumatic 11
Rheumatoid Polyarthritis 33
Rheumatism Arthritis 33
Atrophic Arthritis 11

Characteristics:


Inheritance:

Unproved inheritance 57

Classifications:



Summaries for Rheumatoid Arthritis

MedlinePlus Genetics: 42 Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a symmetrical pattern; for example, if joints in the hand are affected, both hands tend to be involved. People with rheumatoid arthritis often report that their joint pain and stiffness is worse when getting out of bed in the morning or after a long rest.Rheumatoid arthritis can also cause inflammation of other tissues and organs, including the eyes, lungs, and blood vessels. Additional signs and symptoms of the condition can include a loss of energy, a low fever, weight loss, and a shortage of red blood cells (anemia). Some affected individuals develop rheumatoid nodules, which are firm lumps of noncancerous tissue that can grow under the skin and elsewhere in the body.The signs and symptoms of rheumatoid arthritis usually appear in mid- to late adulthood. Many affected people have episodes of symptoms (flares) followed by periods with no symptoms (remissions) for the rest of their lives. In severe cases, affected individuals have continuous health problems related to the disease for many years. The abnormal inflammation can lead to severe joint damage, which limits movement and can cause significant disability.

MalaCards based summary: Rheumatoid Arthritis, also known as ra, is related to arthritis and psoriatic arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Rheumatoid Arthritis is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are NF-kappaB Signaling and Genes associated with the development of rheumatoid arthritis. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include Cartilage, joint and bone, and related phenotypes are joint stiffness and fatigue

MedlinePlus: 41 Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness and loss of function in your joints. It can affect any joint but is common in the wrist and fingers. More women than men get rheumatoid arthritis. It often starts in middle age and is most common in older people. You might have the disease for only a short time, or symptoms might come and go. The severe form can last a lifetime. Rheumatoid arthritis is different from osteoarthritis, the common arthritis that often comes with older age. RA can affect body parts besides joints, such as your eyes, mouth and lungs. RA is an autoimmune disease, which means the arthritis results from your immune system attacking your body's own tissues. No one knows what causes rheumatoid arthritis. Genes, environment, and hormones might contribute. Treatments include medicine, lifestyle changes, and surgery. These can slow or stop joint damage and reduce pain and swelling. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

PubMed Health : 63 Rheumatoid arthritis: There are many different rheumatic diseases, but rheumatoid arthritis is probably the most common. In rheumatoid arthritis, people usually have several permanently inflamed joints. This causes the joints to gradually become deformed and stiff. Over time the muscles also weaken. Someone with advanced rheumatoid arthritis may have difficulties with simple tasks such as washing themselves, eating with a knife and fork, or buttoning up a shirt. Other symptoms such as pain and fatigue can be very troublesome too. This disease can also affect other parts of the body, like the blood vessels or certain organs. Rheumatoid arthritis usually gradually worsens over the course of many years. Various treatments can relieve the pain and slow the progression of the disease. Early diagnosis and treatment can help to prevent damage to the joints.

CDC: 2 Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). RA can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

UniProtKB/Swiss-Prot: 73 An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

OMIM®: 57 Rheumatoid arthritis is an inflammatory disease, primarily of the joints, with autoimmune features and a complex genetic component. (180300) (Updated 08-Dec-2022)

Disease Ontology: 11 An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint.

Wikipedia: 75 Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically... more...

Related Diseases for Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2273)
# Related Disease Score Top Affiliating Genes
1 arthritis 34.2 SLC22A4 PTPN22 NFKBIL1 IRF5 CIITA CD244
2 psoriatic arthritis 32.6 SLC22A4 PTPN22 MIR146A
3 systemic lupus erythematosus 32.3 PTPN22 MIR155 MIR150 MIR146A MALAT1 IRF5
4 multiple sclerosis 31.8 PTPN22 MIR155 MIR146A MIR132 CIITA
5 bone inflammation disease 31.7 PTPN22 MIR155 MIR150 MIR146A MIR132
6 arteries, anomalies of 31.4 MIR155 MIR150 MIR146A MIR132
7 immune deficiency disease 31.3 MIR155 MIR150 MIR146A MIR132 MALAT1 CIITA
8 cerebrovascular disease 31.2 MIR155 MIR150 MIR146A MIR132 HOTAIR
9 demyelinating disease 31.2 MIR155 MIR146A MIR132
10 lipoprotein quantitative trait locus 31.1 MIR155 MIR150 MIR146A MIR132 H19
11 lymphatic system disease 30.8 MIR155 MIR150 MIR146A MIR132
12 myeloma, multiple 30.5 UCA1 MIR155 MALAT1 HOTAIR H19
13 parkinson disease, late-onset 30.4 MIR155 MIR146A MIR132 MALAT1 HOTAIR H19
14 leukemia, acute myeloid 30.4 UCA1 MIR155 MIR150 MIR146A MALAT1 HOTAIR
15 pre-eclampsia 30.4 MIR146A MALAT1 HOTAIR H19
16 retinitis pigmentosa 11 30.1 ZFAS1 UCA1 HOTAIR
17 central nervous system disease 30.1 MIR155 MIR150 MIR146A MIR132 H19
18 cervical cancer 30.0 UCA1 MIR155 MALAT1 HOTAIR H19
19 thyroid carcinoma 29.9 UCA1 MALAT1 HOTAIR H19
20 kidney cancer 29.9 MIR150 MALAT1 HOTAIR H19
21 nasopharyngeal carcinoma 29.7 MIR155 MIR150 MIR146A MIR132 MALAT1 HOTAIR
22 thyroid cancer, nonmedullary, 1 29.7 MIR146A MALAT1 HOTAIR H19
23 osteogenic sarcoma 29.6 UCA1 MALAT1 HOTAIR H19
24 renal cell carcinoma, nonpapillary 29.5 UCA1 MIR155 MIR150 MIR146A MIR132 MALAT1
25 tongue squamous cell carcinoma 29.5 UCA1 MIR150 MALAT1
26 pituitary adenoma 29.4 MIR132 MALAT1 HOTAIR H19
27 esophageal cancer 29.3 UCA1 MIR150 MIR146A MALAT1 HOTAIR H19
28 gallbladder cancer 29.2 UCA1 MALAT1 HOTAIR H19
29 oral squamous cell carcinoma 29.1 UCA1 MIR155 MIR150 MIR146A MIR132 MALAT1
30 juvenile rheumatoid arthritis 12.0
31 felty syndrome 11.8
32 rheumatoid arthritis, systemic juvenile 11.7
33 autoimmune disease 11.6
34 rheumatoid arthritis interstitial lung disease 11.6
35 sjogren syndrome 11.6
36 spondyloarthropathy 1 11.5
37 systemic onset juvenile idiopathic arthritis 11.5
38 synovitis 11.4
39 interstitial lung disease 11.4
40 fibromyalgia 11.4
41 polyarticular onset juvenile idiopathic arthritis 11.4
42 carpal tunnel syndrome 11.4
43 rheumatoid vasculitis 11.4
44 progressive pseudorheumatoid dysplasia 11.4
45 osteoarthritis 11.4
46 systemic scleroderma 11.3
47 arthropathy 11.3
48 serum amyloid a amyloidosis 11.3
49 palindromic rheumatism 11.3
50 mixed connective tissue disease 11.3

Comorbidity relations with Rheumatoid Arthritis via Phenotypic Disease Network (PDN): (show all 32)


Active Peptic Ulcer Disease Acute Cystitis
Bronchiectasis Bronchitis
Chronic Rheumatic Pericarditis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Esophagitis Felty Syndrome
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Idiopathic Interstitial Pneumonia Immune Deficiency Disease
Iron Deficiency Anemia Mononeuropathy of the Median Nerve, Mild
Neutropenia Olecranon Bursitis
Oral Candidiasis Osteoarthritis
Osteoporosis Perforated Corneal Ulcer
Postinflammatory Pulmonary Fibrosis Premature Ovarian Failure 7
Protein-Energy Malnutrition Scleritis
Sjogren Syndrome Spondyloarthropathy 1
Systemic Lupus Erythematosus Temporal Arteritis

Graphical network of the top 20 diseases related to Rheumatoid Arthritis:



Diseases related to Rheumatoid Arthritis

Symptoms & Phenotypes for Rheumatoid Arthritis

Human phenotypes related to Rheumatoid Arthritis:

30 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 30 HP:0001387
2 fatigue 30 HP:0012378
3 fever 30 HP:0001945
4 arthralgia 30 HP:0002829
5 joint swelling 30 HP:0001386
6 weight loss 30 HP:0001824
7 vasculitis 30 HP:0002633
8 elevated erythrocyte sedimentation rate 30 HP:0003565
9 rheumatoid arthritis 30 HP:0001370
10 rheumatoid factor positive 30 HP:0002923
11 polyarticular arthritis 30 HP:0005764
12 interphalangeal joint erosions 30 HP:0006252
13 digital flexor tenosynovitis 30 HP:0012276
14 elevated circulating c-reactive protein concentration 30 HP:0011227
15 swan neck-like deformities of the fingers 30 HP:0006150
16 anti-citrullinated protein antibody positivity 30 HP:0033034

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Joints:
rheumatoid arthritis

Limbs:
rheumatoid nodules

Vascular:
rheumatoid vasculitis

Neuro:
rheumatoid vasculitic mononeuritis

Immunology:
hla-drb1 association

Pulm:
rheumatoid lung disease

Heme:
felty syndrome

Clinical features from OMIM®:

180300 (Updated 08-Dec-2022)

UMLS symptoms related to Rheumatoid Arthritis:


back pain; sciatica; muscle cramp

Drugs & Therapeutics for Rheumatoid Arthritis

PubMed Health treatment related to Rheumatoid Arthritis: 63

Rheumatoid arthritis is treated with both medication and non-drug approaches, such as physiotherapy . There are also various support aids available for making everyday tasks easier. Which of these treatments are suitable options will depend on, for example, how severe the inflammation and the symptoms are, how advanced the disease is, the expected progression of the disease – and how well previous treatments have worked. Medication can reduce inflammation and help keep the disease from getting worse, relieve symptoms like pain and swelling, and help people move their joints more easily again, or at least maintain joint flexibility for as long as possible. There is currently no cure for rheumatoid arthritis . Physiotherapy and sports can help improve or maintain flexibility, strength and joint function. Many types of sports are suitable for people who have rheumatoid arthritis , including cycling, brisk walking, dancing, aerobics, strength training , swimming and water aerobics. Occupational therapy can be used to maintain your flexibility and hand strength, and to learn how to cope with rheumatoid arthritis in everyday life. Psychological treatments are also sometimes used to help relieve pain and minimize the impact it has on everyday life. They are also intended to help relieve disease-related anxiety and depression that some people develop. Support aids are designed to help compensate for physical limitations and help with daily activities. These include orthopedic shoe inserts, grabbing aids and specially designed cutlery.

Drugs for Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 523)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
8
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
9
Sulfasalazine Approved Phase 4 599-79-1 5353980 5339 5359476
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
13
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
15
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744
16
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
17
Valdecoxib Approved, Investigational, Withdrawn Phase 4 181695-72-7 119607
18
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
19
Pheniramine Approved Phase 4 86-21-5 4761
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
21
Calcium carbonate Approved, Investigational Phase 4 471-34-1
22
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
23
Promethazine Approved, Investigational Phase 4 60-87-7 4927
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
27
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
30
Ibuprofen Approved Phase 4 15687-27-1 3672
31
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
32
Milnacipran Approved, Investigational Phase 4 92623-85-3, 96847-54-0 11622909 65833 6917779
33
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
34
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850 155817470
35
Ticagrelor Approved Phase 4 274693-27-5 9871419
36
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
39
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
40
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
41
Coal tar Approved Phase 4 8007-45-2
42
Upadacitinib Approved, Investigational Phase 4 1310726-60-3 76829165 58557659
43
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
44
Rituximab Approved Phase 4 174722-31-7
45
Adalimumab Approved, Experimental Phase 4 331731-18-1
46
Certolizumab pegol Approved Phase 4 428863-50-7
47
Infliximab Approved Phase 4 170277-31-3
48
Golimumab Approved Phase 4 476181-74-5
49
Hydroxychloroquine Approved Phase 4 118-42-3 3652
50
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523

Interventional clinical trials:

(show top 50) (show all 2780)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
2 Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis. Unknown status NCT02242474 Phase 4 Anti-TNF suspended perioperatively;Anti-TNFα continued perioperatively
3 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
4 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
5 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
6 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
7 Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA) Unknown status NCT03895879 Phase 4 Tocilizumab
8 Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis Unknown status NCT04201886 Phase 4
9 Towards Efficient Prediction and Prevention of Rheumatoid Arthritis Unknown status NCT04115397 Phase 4 Zoledronic Acid;Placebo
10 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
11 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Unknown status NCT03016884 Phase 4
12 Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail Unknown status NCT04194827 Phase 4 Adalimumab
13 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
14 Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis Unknown status NCT03882008 Phase 4 Abatacept
15 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
16 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
17 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
18 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
19 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
20 Effect of Sarilumab Therapy on Atherosclerotic Disease Assessed by Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Rheumatoid Arthritis Unknown status NCT04350216 Phase 4 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
21 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Unknown status NCT03781310 Phase 4 Tocilizumab
22 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
23 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
24 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
25 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
26 Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study Unknown status NCT04066803 Phase 4 MTX;Folic Acid;DMARDs
27 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
28 Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial Unknown status NCT03227419 Phase 4 Tocilizumab Prefilled Syringe;Abatacept Prefilled Syringe
29 Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis Unknown status NCT04464642 Phase 4 Methotrexate;Tofacitinib
30 Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial Unknown status NCT01793519 Phase 4 Etanercept;Infliximab;Adalimumab;Placebo
31 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
32 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
33 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
34 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
35 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
36 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
37 Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population? Unknown status NCT02936180 Phase 4
38 Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China Unknown status NCT02837978 Phase 4 Tacrolimus;MTX
39 Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Unknown status NCT01907230 Phase 4 Entecavir
40 The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Unknown status NCT03886038 Phase 4
41 Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial Unknown status NCT04222920 Phase 4 Adalimumab
42 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
43 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
44 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
45 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
46 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
47 Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept Completed NCT00768053 Phase 4 Etanercept
48 The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis Completed NCT02585258 Phase 4 Prednisolone
49 The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab Completed NCT00246064 Phase 4 infliximab
50 RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function. Completed NCT01548768 Phase 4 TNF inhibitors;DMARDs

Search NIH Clinical Center for Rheumatoid Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ACETYLSALICYLATE SODIUM
adalimumab
anakinra
Aspirin
ASPIRIN PWDR
Auranofin
Aurothioglucose
Azathioprine
Captopril
celecoxib
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
choline salicylate
Cyclosporine
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Enalapril
Enalapril Maleate
Enalaprilat
Etanercept
Etodolac
Fenoprofen
Fenoprofen Calcium
Fish Oils
Flurbiprofen
Flurbiprofen sodium
Gold
Gold Sodium Thiomalate
Hydroxychloroquine
Hydroxychloroquine Sulfate
Ibuprofen
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Ketoprofen
KETOPROFEN PWDR
leflunomide
Methotrexate
Methotrexate Sodium
nabumetone
Naproxen
Naproxen sodium
oxaprozin
Penicillamine
Piroxicam
solufenum
Sulfasalazine
Sulindac
Thalidomide
tocilizumab
tofacitinib
Tolmetin
Tolmetin Sodium
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Rheumatoid Arthritis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: arthritis, rheumatoid

Genetic Tests for Rheumatoid Arthritis

Genetic tests related to Rheumatoid Arthritis:

# Genetic test Affiliating Genes
1 Rheumatoid Arthritis 28 CD244 CIITA IL10 NFKBIL1 PTPN22 SLC22A4

Anatomical Context for Rheumatoid Arthritis

Organs/tissues related to Rheumatoid Arthritis:

FMA: Joint
MalaCards : Bone, Bone Marrow, Heart, Skin, Lung, T Cells, Placenta
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Rheumatoid Arthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease

Publications for Rheumatoid Arthritis

Articles related to Rheumatoid Arthritis:

(show top 50) (show all 33829)
# Title Authors PMID Year
1
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. 53 62 57 5
19898480 2009
2
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. 53 62 57 5
17599733 2007
3
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. 53 62 57 5
15208781 2004
4
Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. 62 57 5
18794858 2008
5
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. 62 57 5
17436241 2007
6
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. 62 57 5
14608356 2003
7
Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. 62 57 5
12509789 2003
8
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 57 5
17554300 2007
9
A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. 53 62 57
20453841 2010
10
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. 53 62 57
19503088 2009
11
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. 53 62 57
18794853 2008
12
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. 53 62 5
17170052 2007
13
BLyS and APRIL in rheumatoid arthritis. 53 62 57
16239971 2005
14
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. 53 62 57
16175503 2005
15
Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. 53 62 57
14558082 2003
16
Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. 53 62 57
12847677 2003
17
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. 53 62 57
11477412 2001
18
TLR1/2 and 5 induce elevated cytokine levels from rheumatoid arthritis monocytes independent of ACPA or RF autoantibody status. 62 5
32594150 2020
19
Genetics of rheumatoid arthritis contributes to biology and drug discovery. 62 57
24390342 2014
20
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. 62 57
22290871 2012
21
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. 62 57
21211616 2011
22
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. 62 57
20453842 2010
23
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. 62 57
19898481 2009
24
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. 62 57
19359276 2009
25
Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. 53 57
18759272 2008
26
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. 53 62 46
18759964 2008
27
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. 62 57
17982456 2007
28
Rheumatoid arthritis association at 6q23. 62 57
17982455 2007
29
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. 62 57
17804836 2007
30
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. 62 57
17804842 2007
31
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. 62 57
16906016 2006
32
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. 62 57
16691188 2006
33
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. 53 5
16273109 2005
34
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. 62 57
16127437 2005
35
Whole genome association study of rheumatoid arthritis using 27 039 microsatellites. 62 57
16000323 2005
36
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. 62 5
15821736 2005
37
4-1BB-mediated immunotherapy of rheumatoid arthritis. 62 57
15448685 2004
38
Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. 62 57
14578453 2003
39
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. 62 57
12833157 2003
40
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. 62 57
12847215 2003
41
Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16. 62 57
12746892 2003
42
Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. 62 57
12181776 2002
43
High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. 62 57
11555626 2001
44
Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. 62 57
11369787 2001
45
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. 62 57
11254450 2001
46
A second susceptibility gene for developing rheumatoid arthritis in the human MHC is localized within a 70-kb interval telomeric of the TNF genes in the HLA class III region. 62 57
11170743 2001
47
Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. 62 57
9843218 1998
48
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. 62 57
9724775 1998
49
HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis. 62 57
9410900 1997
50
Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. 62 57
8909256 1996

Variations for Rheumatoid Arthritis

ClinVar genetic disease variations for Rheumatoid Arthritis:

5 (show all 29)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PADI4 NM_012387.3(PADI4):c.341-15T>C SNV Association
590790 rs2240340 GRCh37: 1:17662639-17662639
GRCh38: 1:17336144-17336144
2 PADI4 NC_000001.11:g.17157671G>T SNV Association
590889 rs1557787212 GRCh37: 1:17484166-17484166
GRCh38: 1:17157671-17157671
3 SOCS1 NC_000016.10:g.11254001T>C SNV Affects
801021 rs4780355 GRCh37: 16:11347858-11347858
GRCh38: 16:11254001-11254001
4 PADI2 NM_007365.3(PADI2):c.*258A>T SNV Association
972888 rs2235926 GRCh37: 1:17395281-17395281
GRCh38: 1:17068786-17068786
5 PADI2 NM_007365.3(PADI2):c.1159-39G>A SNV Association
972889 rs2057094 GRCh37: 1:17405949-17405949
GRCh38: 1:17079454-17079454
6 PADI2 NM_007365.3(PADI2):c.729T>G (p.Gly243=) SNV Association
972890 rs2076615 GRCh37: 1:17413121-17413121
GRCh38: 1:17086626-17086626
7 PADI2 NM_007365.3(PADI2):c.92+1006C>A SNV Association
972891 rs1005753 GRCh37: 1:17444769-17444769
GRCh38: 1:17118274-17118274
8 PADI4 NM_012387.3(PADI4):c.163G>A (p.Gly55Ser) SNV Association
972892 rs11203366 GRCh37: 1:17657534-17657534
GRCh38: 1:17331039-17331039
9 PADI4 NM_012387.3(PADI4):c.245T>C (p.Val82Ala) SNV Association
972893 rs11203367 GRCh37: 1:17657616-17657616
GRCh38: 1:17331121-17331121
10 PADI4 NM_012387.3(PADI4):c.349T>C (p.Leu117=) SNV Association
972894 rs1748033 GRCh37: 1:17662662-17662662
GRCh38: 1:17336167-17336167
11 PADI4 NM_012387.3(PADI4):c.335G>C (p.Gly112Ala) SNV Association
972895 rs874881 GRCh37: 1:17660499-17660499
GRCh38: 1:17334004-17334004
12 IRF5 NM_001098629.3(IRF5):c.-12+198= SNV Pathogenic
3396 rs1432329681 GRCh37: 7:128578301-128578301
GRCh38: 7:128938247-128938247
13 TLR1 NM_003263.4(TLR1):c.2036T>C (p.Ile679Thr) SNV Pathogenic
983492 GRCh37: 4:38798417-38798417
GRCh38: 4:38796796-38796796
14 TLR1 NM_003263.4(TLR1):c.1324T>C (p.Cys442Arg) SNV Pathogenic
983493 GRCh37: 4:38799129-38799129
GRCh38: 4:38797508-38797508
15 CHRNG NM_005199.5(CHRNG):c.994C>T (p.Arg332Trp) SNV Pathogenic
983491 GRCh37: 2:233408368-233408368
GRCh38: 2:232543658-232543658
16 NFKBIL1 NM_001144962.2(NFKBIL1):c.-13+590T>A SNV Risk Factor
8475 GRCh37: 6:31515340-31515340
GRCh38: 6:31547563-31547563
17 CIITA NM_000246.3(CIITA):c.-286G= SNV Risk Factor
9546 rs3087456 GRCh37: 16:10970902-10970902
GRCh38: 16:10877045-10877045
18 CIITA NM_000246.4(CIITA):c.170C>A (p.Ala57Asp) SNV Likely Pathogenic
528781 rs1555500356 GRCh37: 16:10989256-10989256
GRCh38: 16:10895399-10895399
19 CD244 NM_016382.4(CD244):c.834+526A>G SNV Risk Factor
4895 rs3766379 GRCh37: 1:160807715-160807715
GRCh38: 1:160837925-160837925
20 SLC22A4 NM_003059.3(SLC22A4):c.393+6607C>T SNV Risk Factor
5749 rs3792876 GRCh37: 5:131637309-131637309
GRCh38: 5:132301616-132301616
21 AP4B1-AS1, PTPN22 NM_015967.8(PTPN22):c.1858= (p.Trp620=) SNV Risk Factor
8909 rs2476601 GRCh37: 1:114377568-114377568
GRCh38: 1:113834946-113834946
22 SUPT20H NM_001014286.3(SUPT20H):c.73A>T (p.Lys25Ter) SNV Risk Factor
565291 rs1566328963 GRCh37: 13:37622040-37622040
GRCh38: 13:37047903-37047903
23 CIITA NM_000246.4(CIITA):c.2817-8C>G SNV Uncertain Significance
827997 rs775728920 GRCh37: 16:11004037-11004037
GRCh38: 16:10910180-10910180
24 CIITA NM_000246.4(CIITA):c.413T>C (p.Val138Ala) SNV Uncertain Significance
569422 rs142469968 GRCh37: 16:10992836-10992836
GRCh38: 16:10898979-10898979
25 CIITA NM_000246.4(CIITA):c.2375A>T (p.Tyr792Phe) SNV Uncertain Significance
992562 rs1234424650 GRCh37: 16:11001724-11001724
GRCh38: 16:10907867-10907867
26 CIITA NM_000246.4(CIITA):c.3344G>A (p.Ser1115Asn) SNV Uncertain Significance
598994 rs138790505 GRCh37: 16:11017111-11017111
GRCh38: 16:10923254-10923254
27 CIITA NM_000246.4(CIITA):c.286G>A (p.Ala96Thr) SNV Uncertain Significance
528783 rs149253747 GRCh37: 16:10989612-10989612
GRCh38: 16:10895755-10895755
28 CIITA NM_000246.4(CIITA):c.3217T>A (p.Ser1073Thr) SNV Uncertain Significance
571174 rs761139192 GRCh37: 16:11016091-11016091
GRCh38: 16:10922234-10922234
29 CIITA NM_000246.4(CIITA):c.965C>T (p.Pro322Leu) SNV Uncertain Significance
991982 rs74806537 GRCh37: 16:10998628-10998628
GRCh38: 16:10904771-10904771

UniProtKB/Swiss-Prot genetic disease variations for Rheumatoid Arthritis:

73
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Copy number variations for Rheumatoid Arthritis from CNVD:

6 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14772 1 110031964 110037890 Loss,gain GSTM1 Rheumatoid arthritis
2 21793 1 161592989 161601158 Copy number FCGR3B Rheumatoid arthritis
3 71428 12 69818942 132349534 Copy number Rheumatoid arthritis
4 107131 17 1225928 31649829 Copy number CCL3L3 Rheumatoid arthritis
5 107140 17 1225928 31649843 Copy number CCL3L1 Rheumatoid arthritis
6 107141 17 1225928 31649843 Copy number CCL3L1 Rheumatoid arthritis
7 107161 17 1242109 31665953 Copy number CCL4L2 Rheumatoid arthritis
8 110230 17 31562580 31665959 Copy number CCL4L1 Rheumatoid arthritis
9 110280 17 31800000 38100000 Copy number CCL3L1 Rheumatoid arthritis
10 110281 17 31800000 38100000 Copy number CCL3L1 Rheumatoid arthritis
11 110287 17 31800000 38100000 Copy number CCL4L1 Rheumatoid arthritis
12 112711 17 40930407 78774742 Copy number Rheumatoid arthritis
13 139338 2 179004449 242951149 Copy number Rheumatoid arthritis
14 195356 5 150157836 180857866 Copy number Rheumatoid arthritis
15 195376 5 150183562 180857866 Copy number Rheumatoid arthritis
16 209407 6 2614953 31491069 Copy number MICA Rheumatoid arthritis
17 210790 6 31416574 170899992 Copy number Rheumatoid arthritis
18 211218 6 32451664 32846093 Deletion HLA-DRB1 Rheumatoid arthritis
19 211340 6 32582950 170899992 Copy number Rheumatoid arthritis
20 211358 6 32593131 32665540 Copy number HLA-DRB5 Rheumatoid arthritis
21 211386 6 32609209 170899992 Copy number Rheumatoid arthritis
22 212283 6 3674895 32665540 Copy number HLA-DRB1 Rheumatoid arthritis
23 212429 6 3795995 32719407 Copy number HLA-DQA1 Rheumatoid arthritis
24 212450 6 3813334 32742444 Copy number HLA-DQB1 Rheumatoid arthritis
25 227677 7 71800000 77400000 Decrease NCF1 Rheumatoid arthritis
26 300307 10 5316846 5321159 Deletion C4A Rheumatoid arthritis
27 300308 10 5316846 5321159 Deletion HLA-DRB1 Rheumatoid arthritis
28 300691 13 20783404 20811429 Deletion C4A Rheumatoid arthritis
29 300692 13 20783404 20811429 Deletion HLA-DRB1 Rheumatoid arthritis
30 300834 14 21834952 21881469 Deletion C6 Rheumatoid arthritis
31 300835 14 21834952 21881469 Deletion HLA-DRB1 Rheumatoid arthritis
32 300836 14 21834952 21999998 Deletion C5 Rheumatoid arthritis
33 300837 14 21834952 21999998 Deletion HLA-DRB1 Rheumatoid arthritis
34 302900 19 2051346 2066790 Deletion C12orf57 Rheumatoid arthritis
35 302901 19 2051346 2066790 Deletion HLA-DRB1 Rheumatoid arthritis
36 302902 19 2060157 2066790 Deletion C9 Rheumatoid arthritis
37 302903 19 2060157 2066790 Deletion HLA-DRB1 Rheumatoid arthritis
38 303106 2 208064035 208066083 Deletion CDCA3 Rheumatoid arthritis
39 303107 2 208064035 208066083 Deletion HLA-DRB1 Rheumatoid arthritis
40 303300 20 35438689 35485260 Deletion C7 Rheumatoid arthritis
41 303301 20 35438689 35485260 Deletion HLA-DRB1 Rheumatoid arthritis

Expression for Rheumatoid Arthritis

LifeMap Discovery
Genes differentially expressed in tissues of Rheumatoid Arthritis patients vs. healthy controls: 35 (show top 50) (show all 117)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IGKV4-1 immunoglobulin kappa variable 4-1 Cartilage + 8.77 0.000
2 IGHM immunoglobulin heavy constant mu Cartilage + 8.02 0.000
3 JCHAIN joining chain of multimeric IgA and IgM Cartilage + 7.60 0.000
4 IGKV1-5 immunoglobulin kappa variable 1-5 Cartilage + 7.45 0.000
5 IGLV2-23 immunoglobulin lambda variable 2-23 Cartilage + 7.41 0.000
6 IGKC immunoglobulin kappa constant Cartilage + 7.39 0.000
7 IGL immunoglobulin lambda locus Cartilage + 7.15 0.000
8 CYP4B1 cytochrome P450 family 4 subfamily B member 1 Cartilage - 7.13 0.000
9 IGLJ3 immunoglobulin lambda joining 3 Cartilage + 7.05 0.000
10 CXCL13 C-X-C motif chemokine ligand 13 Cartilage + 6.45 0.000
11 MMP1 matrix metallopeptidase 1 Cartilage + 6.43 0.000
12 IGLV3-19 immunoglobulin lambda variable 3-19 Cartilage + 6.32 0.000
13 POU2AF1 POU class 2 homeobox associating factor 1 Cartilage + 6.00 0.000
14 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Cartilage - 5.82 0.000
15 IGHD immunoglobulin heavy constant delta Cartilage + 5.82 0.000
16 NKG7 natural killer cell granule protein 7 Cartilage + 5.65 0.000
17 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Cartilage - 5.35 0.000
18 TNFRSF17 TNF receptor superfamily member 17 Cartilage + 5.26 0.000
19 SDC1 syndecan 1 Cartilage + 5.26 0.000
20 IGKV3-20 immunoglobulin kappa variable 3-20 Cartilage + 5.23 0.000
21 ANGPTL7 angiopoietin like 7 Cartilage - 5.08 0.000
22 PCK1 phosphoenolpyruvate carboxykinase 1 Cartilage - 5.07 0.000
23 IGLL3P immunoglobulin lambda like polypeptide 3, pseudogene Cartilage + 4.98 0.000
24 CCL18 C-C motif chemokine ligand 18 Cartilage + 4.97 0.000
25 IGLV1-40 immunoglobulin lambda variable 1-40 Cartilage + 4.87 0.000
26 FAM107A family with sequence similarity 107 member A Cartilage - 4.85 0.000
27 CD52 CD52 molecule Cartilage + 4.64 0.000
28 CCL5 C-C motif chemokine ligand 5 Cartilage + 4.56 0.000
29 APOD apolipoprotein D Cartilage - 4.40 0.000
30 ADAM28 ADAM metallopeptidase domain 28 Cartilage + 4.12 0.000
31 MXRA5 matrix remodeling associated 5 Cartilage + 4.10 0.000
32 FKBP5 FKBP prolyl isomerase 5 Cartilage - 4.09 0.002
33 PLIN1 perilipin 1 Cartilage - 4.04 0.000
34 DOCK10 dedicator of cytokinesis 10 Cartilage + 4.04 0.000
35 NPAS2 neuronal PAS domain protein 2 Cartilage - 4.01 0.000
36 DDX3Y DEAD-box helicase 3 Y-linked Cartilage - 3.91 0.023
37 LILRB2 leukocyte immunoglobulin like receptor B2 Cartilage + 3.89 0.000
38 PTPRC protein tyrosine phosphatase receptor type C Cartilage + 3.87 0.000
39 NCF1C neutrophil cytosolic factor 1C pseudogene Cartilage + 3.87 0.000
40 MAOA monoamine oxidase A Cartilage - 3.85 0.000
41 AQP9 aquaporin 9 Cartilage + 3.84 0.000
42 ZBTB16 zinc finger and BTB domain containing 16 Cartilage - 3.84 0.000
43 ADCY2 adenylate cyclase 2 Cartilage - 3.83 0.000
44 TRAF3IP3 TRAF3 interacting protein 3 Cartilage + 3.82 0.000
45 IGKV1D-8 immunoglobulin kappa variable 1D-8 Cartilage + 3.81 0.000
46 IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Cartilage + 3.79 0.000
47 IL32 interleukin 32 Cartilage + 3.79 0.000
48 TOX3 TOX high mobility group box family member 3 Cartilage - 3.78 0.005
49 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Cartilage + 3.76 0.000
50 SEMA4D semaphorin 4D Cartilage + 3.75 0.000
Search GEO for disease gene expression data for Rheumatoid Arthritis.

Pathways for Rheumatoid Arthritis

Pathways related to Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TLR1 PTPN22 IRF5 CIITA
2 10.28 SLC22A4 PTPN22 IRF5 CIITA CD244

GO Terms for Rheumatoid Arthritis

Biological processes related to Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of tumor necrosis factor production GO:0032720 9.72 PTPN22 NFKBIL1 MIR132
2 negative regulation of interleukin-6 production GO:0032715 9.56 PTPN22 MIR146A MIR132
3 positive regulation of granzyme B production GO:0071663 9.46 PTPN22 CD244
4 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.13 MIR150 MIR146A MIR132
5 negative regulation of interleukin-8 production GO:0032717 8.92 PTPN22 MIR146A MIR132

Molecular functions related to Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 8.92 MIR155 MIR150 MIR146A MIR132

Sources for Rheumatoid Arthritis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....